Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pazopanib, pharmaceutical composition, injection, preparation method and application

A technology of pazopanib and its composition, applied in the fields of application, pharmaceutical composition, injection and preparation and application of pazopanib, capable of solving the problems of no introduction of acute lung injury, no acute lung injury, etc.

Pending Publication Date: 2021-09-07
青晓制药公司
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Chinese patent document (CN102970871A) discloses a kind of pharmaceutical composition and preparation method thereof, and this pharmaceutical composition comprises the modified cyclodextrin of 10mg / ml pazopanib, 2~13% weight, carries out the modified cyclodextrin The pKa of pazopanib and modified cyclodextrin in water is selected such that the modified cyclodextrin is lower than the pKa of pazopanib alone in water, the pH is 3.5-5.7, and the osmolality is 200-400mOsm Tonicity modifier and water are required, the pharmaceutical composition is only applied in eye drops, there is no presentation on the treatment of acute lung injury
[0007] In summary, although it is disclosed in the prior art that pazopanib can be used to treat pulmonary fibrosis, there is no report that it can be used to treat acute lung injury
And when pazopanib is used for the treatment of pulmonary fibrosis, it can only be taken orally, and a relatively large amount of pazopanib is needed to achieve the defect of treating pulmonary fibrosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pazopanib, pharmaceutical composition, injection, preparation method and application
  • Application of pazopanib, pharmaceutical composition, injection, preparation method and application
  • Application of pazopanib, pharmaceutical composition, injection, preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Embodiment 1 pharmaceutical composition and preparation method thereof

[0066] 1. Taking the pharmaceutical composition as 1 mL; the concentration of pazopanib hydrochloride in the pharmaceutical composition is 5 mg / mL, and the concentration of hydroxypropyl-β-cyclodextrin in the pharmaceutical composition is 200 mg / mL; the concentration of the pharmaceutical composition The pH is 3.25.

[0067] 2. The preparation method of the above-mentioned pharmaceutical composition specifically comprises the following steps:

[0068] (1) Pour 5 mg of pazopanib hydrochloride into a container containing 1 mL of 200 mg / mL hydroxypropyl-β-cyclodextrin solution, the solvent in the hydroxypropyl-β-cyclodextrin solution For injection water. The concentration of pazopanib hydrochloride in the mixed solution is 5 mg / mL, and the concentration of hydroxypropyl-β-cyclodextrin is 200 mg / mL; among them, the water for injection needs to be filled with nitrogen for 30 minutes before use;

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of pazopanib, a pharmaceutical composition, an injection, a preparation method and application. The pharmaceutical composition comprises the following components: pazopanib, a cyclodextrin solubilizer and a solvent, wherein the mass ratio of pazopanib to the cyclodextrin solubilizer is 1: (13-100); and based on 1mL of the pharmaceutical composition, the concentration of the cyclodextrin solubilizer in the pharmaceutical composition is 6-330mg / mL. The pharmaceutical composition prepared by the invention can be used for treating diseases such as acute lung injury, pulmonary fibrosis and acute respiratory distress syndrome, and the treatment aim can be achieved by using a small amount of pazopanib; and moreover, the pharmaceutical composition is high in bioavailability, high in stability and low in impurity content, and the phenomenon of drug accumulation is avoided.

Description

[0001] This application claims the priority of the Chinese patent application CN202010178371.4 with the filing date of March 13, 2020. This application cites the full text of the above-mentioned Chinese patent application. technical field [0002] The invention relates to the application of pazopanib, a pharmaceutical composition, an injection, a preparation method and application. Background technique [0003] Pazopanib hydrochloride is an oral VEGF-2 inhibitor developed by GlaxoSmithKline. The drug also has inhibitory effects on PDGFR and c-KIT tyrosine kinases at the same time, not only has inhibitory effects on renal cell carcinoma, but also has inhibitory effects on non-small cell carcinoma, breast cancer, sarcoma and other tumors. [0004] Chinese patent document (CN102970871A) discloses a kind of pharmaceutical composition and preparation method thereof, and this pharmaceutical composition comprises the modified cyclodextrin of 10mg / ml pazopanib, 2~13% weight, carrie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61K9/08A61K47/40A61P11/00
CPCA61K31/506A61K9/08A61K9/0019A61K47/40A61P11/00
Inventor 李小锋罗浩贤
Owner 青晓制药公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products